Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Cutaneous myiasis associated with scalp psoriasis

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis Federica Ricceri, MD, Leonardo.

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Permanent chemotherapy-induced alopecia: A review

Pediatric teledermatology: Observations based on 429 consults

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Applying for dermatology residency is difficult and expensive

Pain and nonmelanoma skin cancer in transplant patients

Brachioradial pruritus: A trigger for generalization of itch

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Treatment of psoriasis vulgaris using low-dose naltrexone

SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss Elise A. Olsen, MD, Douglas Canfield, BS Journal.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

What is an “eosinophilic phenotype” of asthma?

Hugh Gloster, MD, Chesahna Kindred, MBA

Seasonal patterns in alopecia areata, totalis, and universalis

Appearance of lentigines in psoriasis patients treated with apremilast

Medicaid acceptance among pediatric dermatologists

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Blake R. Zelickson, MD, PhD, Leonard H. Goldberg, MD, Marc K

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Itching as a systemic disease

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil Yosipovitch, MD Journal of the American Academy of Dermatology Volume 70, Issue 2, Pages 390-391 (February 2014) DOI: 10.1016/j.jaad.2013.09.030 Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Lack of correlation between modified Psoriasis Area and Severity Index (mPASI) and pruritus visual analog scale (VAS) scores of study patients with psoriasis. Pruritus VAS scores, measuring pruritus severity, and mPASI scores, measuring psoriasis disease severity, were recorded in 157 patients at baseline enrolling for a clinical trial. The Psoriasis Area and Severity Index (PASI) score was modified as the scalp and face were not assessed. In all, 160 patients were enrolled in the trial, but 3 patients were excluded from the correlation analysis as they did not have properly recorded VAS or mPASI scores. The correlation between VAS and mPASI scores in these patients was measured through the coefficient of determination (R2). A lack of correlation between VAS and mPASI scores was found. The R2 value was 3.8%, meaning that only 3.8% of the variability in pruritus severity could be explained by its relationship to psoriasis disease severity. FAS, Full analysis set. Journal of the American Academy of Dermatology 2014 70, 390-391DOI: (10.1016/j.jaad.2013.09.030) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions